论文部分内容阅读
目的研究舒洛地特联合瑞格列奈治疗糖尿病肾病的临床疗效。方法选取2014年5月—2015年2月重庆市南岸区人民医院收治的糖尿病肾病患者200例,随机分为对照组和治疗组,每组各100例。对照组口服瑞格列奈片,0.5 mg/次,2次/d,连续使用2周后根据患者表现出来的具体症状调整用药剂量。治疗组在对照组治疗基础上口服舒洛地特软胶囊,1粒/次,2次/d。两组均连续治疗4个月。观察两组的临床疗效,同时比较治疗前后两组患者空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(Hb A1c)、体质量指数(BMI)、24 h尿蛋白、血肌酐(Scr)、尿素氮(BUN)、IL-6、IL-10、TNF-α的变化情况。结果治疗后,对照组和治疗组的总有效率分别为88.0%、96.0%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者FPG、2 h PBG、Hb A1c、24 h尿蛋白、Scr、BUN、IL-6、IL-10、TNF-α均显著降低,同组治疗前后差异有统计学意义(P<0.05);治疗后治疗组这些观察指标的改善程度优于对照组,两组比较差异有统计学意义(P<0.05);治疗后治疗组患者BMI较治疗前显著降低,对照组无明显变化,两组比较差异有统计学意义(P<0.05)。结论舒洛地特联合瑞格列奈治疗糖尿病肾病具有较好的临床疗效,可较好的控制患者的血糖水平,减轻肾脏损害,具有一定的临床推广应用价值。
Objective To study the clinical efficacy of sulodentid combined with repaglinide in the treatment of diabetic nephropathy. Methods From May 2014 to February 2015, 200 patients with diabetic nephropathy admitted to Nan’an District People’s Hospital of Chongqing were randomly divided into control group and treatment group, with 100 cases in each group. Control group oral repaglinide tablets, 0.5 mg / time, 2 times / d, continuous use for 2 weeks according to the patient to show the specific symptoms to adjust the dose. Treatment group in the control group on the basis of oral treatment with sulodexide soft capsules, 1/2 times / d. Two groups were treated for 4 months. The clinical effects of two groups were observed. The levels of fasting blood glucose (FPG), 2 h PG, Hb A1c, BMI, 24 h urinary protein, Serum creatinine (Scr), blood urea nitrogen (BUN), IL-6, IL-10, TNF-α changes. Results After treatment, the total effective rate of the control group and the treatment group was 88.0% and 96.0% respectively, with significant difference between the two groups (P <0.05). The levels of FPG, 2 h PBG, Hb A1c, 24h urinary protein, Scr, BUN, IL-6, IL-10 and TNF-αwere significantly decreased in both groups after treatment <0.05). After treatment, the improvement of these indexes in the treatment group was better than that in the control group, with significant difference between the two groups (P <0.05); after treatment, the BMI in the treatment group was significantly lower than that before treatment, but there was no significant change in the control group , The difference between the two groups was statistically significant (P <0.05). Conclusion The combination of sulodentia and repaglinide has a good clinical curative effect on diabetic nephropathy, which can control the blood glucose level and reduce the renal damage, and has certain clinical application value.